Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2007-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.298.10.1180PMID 17848652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

  2006cited by this paper
• Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

  2006cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

  2004cited by this paper
• Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes

  2004cited by this paper
• Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Glitazones and heart failure: critical appraisal for the clinician.

  2003cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)

  2001cited by this paper
• Peroxisome proliferator-activated receptors in inflammation control.

  2001cited by this paper
• Medical significance of peroxisome proliferator-activated receptors.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.

  1988cited by this paper

• Prevalence and factors associated with Chinese herbal medicine use among middle-aged and older Chinese adults with diabetes mellitus

  2025cites this paper
• Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

  2025cites this paper
• Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.

  2025cites this paper
• Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes

  2025cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.

  2025cites this paper
• Intersecting Burdens: Type 2 Diabetes Diagnosis, Risk, and Pharmacological Management Among People Living With HIV.

  2025cites this paper
• Design and synthesis of a novel quinoline thiazolidinedione hybrid as a potential antidiabetic PPARγ modulator

  2025cites this paper
• Metabolic reprogramming in cardiometabolic syndrome: mechanisms, biomarkers, and therapeutic approaches.

  2025cites this paper
• Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes.

  2025cites this paper
• Comprehensive Review on Oral Hypoglycemic Agents in Geriatric Diabetic Patients

  2025cites this paper
• The role of the PPAR system in diabetic cardiovascular risk and beyond.

  2025cites this paper
• Cellular and Molecular Pathways in Diabetes-Associated Heart Failure: Emerging Mechanistic Insights and Therapeutic Opportunities

  2025cites this paper
• Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System

  2025cites this paper
• Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment

  2025cites this paper
• Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations

  2025cites this paper
• Diabetes and calcific aortic valve disease: implications of glucose-lowering medication as potential therapy

  2025cites this paper
• Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events

  2025cites this paper
• Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials

  2025cites this paper
• Positionspapier der DDG, DGA, DGG und DeGiR zur Diagnostik und Behandlung der pAVK bei Diabetes mellitus

  2025cites this paper
• Effect of Tirzepatide on Cardiovascular Outcomes

  2025cites this paper
• Beyond boundaries: exploring the latest guidelines for diabetes and cardiovascular health

  2024cites this paper
• Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

  2024cites this paper
• PPARγ Agonist Pioglitazone Prevents Hypoxia-induced Cardiac Dysfunction by Reprogramming Glucose Metabolism

  2024cites this paper
• Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy

  2024cites this paper
• Pioglitazone increases risk of ischemic heart disease in patients with type 2 diabetes receiving insulin.

  2024cites this paper
• ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents

  2024cites this paper
• Diabetes and Heart Failure: A Literature Review, Reflection and Outlook

  2024cites this paper
• Coronary Plaque Regression and Fractional Flow Reserve Improvement in a Chronic Coronary Syndrome Case: Early Optimal Medical Therapy and Fractional Flow Reserve-Computed Tomography Follow-Up Strategy

  2024cites this paper
• Nonalcoholic Fatty Liver Disease as a Potential Risk Factor for Cardiovascular Disease in Patients with Type 2 Diabetes: A Prospective Cohort Study

  2024cites this paper
• Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure

  2024cites this paper
• The effect of hsCRP on TyG index-associated cardiovascular risk in patients with acute coronary syndrome undergoing PCI

  2024cites this paper
• Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone

  2024cites this paper
• Pioglitazone as a potential modulator in autoimmune diseases: a review on its effects in systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and multiple sclerosis

  2024cites this paper
• Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology.

  2024cites this paper
• When cardiovascular medicines should be discontinued.

  2024cites this paper
• A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus

  2024cites this paper
• PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease.

  2024cites this paper
• Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical Evidence—A Narrative Review

  2024cites this paper
• Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets

  2024cites this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

  2023cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cites this paper
• Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study

  2023cites this paper
• The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review

  2023cites this paper
• Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review

  2023influential citation
• Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model

  2023cites this paper
• Phenotyping obesity: A focus on metabolically healthy obesity and metabolically unhealthy normal weight

  2023cites this paper
• NAFLD: An Emerging Causal Factor for Cardiovascular Disease.

  2023cites this paper
• 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

  2023cites this paper
• Signaling pathways and intervention for therapy of type 2 diabetes mellitus

  2023cites this paper
• Medical Therapy Before, During, and After Hospitalization in Medicare Beneficiaries with Heart Failure and Diabetes: The Get With The Guidelines - Heart Failure Registry.

  2023cites this paper
• Peroxisome proliferator-activated receptors, farnesoid X receptor, and dual modulating drugs in hypertension

  2023cites this paper
• The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure.

  2023cites this paper
• Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types

  2023cites this paper
• 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.

  2023cites this paper
• Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)

  2023cites this paper
• Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs

  2023cites this paper
• [Rediscovery of pioglitazone].

  2023cites this paper
• Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022

  2023cites this paper
• PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

  2022influential citation
• Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction

  2022cites this paper
• Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus.

  2022cites this paper
• Targeting triglycerides to lower residual cardiovascular risk

  2022cites this paper
• Antiapoptotic and anti‐inflammatory effects of Pparγ agonist, pioglitazone, reversed Dox‐induced cardiotoxicity through mediating of miR‐130a downregulation in C57BL/6 mice

  2022cites this paper
• Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome

  2022cites this paper
• Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model

  2022cites this paper
• 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.

  2022cites this paper
• Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review

  2022cites this paper
• Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease.

  2022cites this paper
• Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology and molecular docking

  2022cites this paper
• Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome Targets Therapy

  2022cites this paper
• Epigenetics in precision medicine of cardiovascular disease

  2022cites this paper
• Microbiota Comparison of Amur ide (Leuciscus waleckii) Intestine and Waters at Alkaline Water and Freshwater as the Living Environment

  2022cites this paper
• Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus

  2022cites this paper
• Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial

  2022cites this paper
• Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning

  2022cites this paper
• Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice

  2022cites this paper
• Triglyceride-glucose index and non-culprit coronary plaque characteristics assessed by optical coherence tomography in patients following acute coronary syndrome: A cross-sectional study

  2022cites this paper
• Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation

  2022cites this paper
• Determination of pioglitazone hydrochloride by flow injection chemiluminescence tris(2,2'-bipyridyl)ruthenium(II)-silver(III) complex system.

  2022cites this paper
• ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents

  2022cites this paper
• Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history.

  2022cites this paper
• Diabetes and cardiovascular risk according to gender: an overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials.

  2022cites this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

  2022cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.

  2022cites this paper
• Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus

  2022cites this paper
• Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure

  2021cites this paper
• Current treatment paradigms and emerging therapies for NAFLD/NASH.

  2021cites this paper
• Pharmacology of NASH

  2021cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment

  2021cites this paper
• Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.

  2021cites this paper
• Abnormalities of Carbohydrate Metabolism and the Liver

  2021cites this paper
• Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione

  2021cites this paper
• Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

  2021cites this paper
• Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice.

  2021cites this paper
• The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

  2021cites this paper
• Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure

  2021cites this paper
• Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention.

  2021cites this paper